<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03236909</url>
  </required_header>
  <id_info>
    <org_study_id>G170111</org_study_id>
    <nct_id>NCT03236909</nct_id>
  </id_info>
  <brief_title>Expanded Indications in the Adult Cochlear Implant Population</brief_title>
  <official_title>Expanded Indications in the Adult Cochlear Implant Population</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Med-El Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Med-El Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this investigation is to expand FDA-approved labeling for MED-EL cochlear
      implants to include adults who have moderate to profound sensorineural hearing loss and
      obtain limited benefit from appropriately fit hearing aids.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Fifty (50) subjects, 18 years of age and older, will be implanted across the United States
      and Canada. Subjects with moderate to profound bilateral sensorineural hearing loss will be
      implanted with the MED-EL SYNCHRONY/SYNCHRONY PIN Cochlear Implant System. .

      Limited benefit from amplification is defined by test scores of 60% correct or less in the
      ear to be implanted (70% or less in the nonimplanted ear) on monosyllabic words in quiet.
      Subjects will be followed for twelve (12) months post-activation of the SONNETEAS Audio
      Processor.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 16, 2018</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent correct words recognition in quiet in implanted ear</measure>
    <time_frame>Up to twelve (12 months) post-activation</time_frame>
    <description>CNC (Consonant Nucleus Consonant) word scores will be calculated as percent correct at baseline through 6 months and reported as percentage points improved.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent correct of words identified for sentences in noise in implanted ear</measure>
    <time_frame>Up to twelve (12 months) post-activation</time_frame>
    <description>AzBio sentence recognition in noise scores will be calculated as percent correct of words in each sentence at baseline through 6 months and reported as percentage points improved.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient reported improvement in everyday listening conditions</measure>
    <time_frame>Up to twelve (12 months) post -activation</time_frame>
    <description>APHAB (ABBREVIATED PROFILE OF HEARING AID BENEFIT) and SSQ (Spatial and Qualities of Hearing) questionnaires will be used to assess subjective outcomes and reported as improvements from baseline to 6 months post-activation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and proportion of subjects experiencing device related adverse events</measure>
    <time_frame>Up to twelve (12 months) post-activation</time_frame>
    <description>Adverse events will be collected and reported throughout the duration of the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Residual low frequency hearing</measure>
    <time_frame>Up to twelve (12) months post-activation</time_frame>
    <description>HEARRING scale will be used to calculate the percent of hearing preservation for each subject. This data will be summarized through 6 months post-activation.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Hearing Loss, Sensorineural</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MED-EL SYNCHRONY/SYNCHRONY PIN Cochlear Implant System</intervention_name>
    <description>Subjects will be implanted with the MED-EL SYNCHRONY/SYNCHRONY PIN Cochlear Implant System with +FLEX28 or +FLEXSOFT electrode arrays. Subjects will be fit with the SONNETEAS (ear-level) and/or RONDO (single-unit) external audio processors.</description>
    <other_name>SYNCHRONY +FLEXSOFT</other_name>
    <other_name>SYNCHRONY +FLEX28</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults, 18 years of age or older at the time of implantation

          -  Moderate to profound hearing loss in the low frequencies and severe to profound
             hearing loss in the high frequencies, bilaterally as defined by: Low-frequency PTA
             (250, 500, and 1000 Hz) greater than 40 dB High-frequencies not better than 65 dB
             (3000 Hz - 8000 Hz)

          -  Sensorineural hearing loss, demonstrated by an air-bone gap of less than or equal to
             10dB

          -  Limited benefit from appropriately fit hearing aids, defined by CNC word score in
             quiet of 60% or less in the ear to be implanted and 70% or less in the non-implanted
             ear

          -  CNC word score in quiet of greater than or equal to 10% in the ear to be implanted

          -  Evidence of appropriately fit hearing aids as determined by the audiologist

          -  Bilateral hearing aids should be considered standard of care, except in situations
             where the audiologist, physician, or potential subject determines that unilateral fit
             is optimal

          -  Hearing aid fit should be verified through accepted measures such as functional gain
             or real-ear verification

          -  If appropriately fit hearing aids have not been worn within the last year, a 30-day
             hearing aid trial must be completed prior to enrollment in the study

          -  Fluent in English

          -  No radiological contraindications

          -  Ability to undergo general anesthesia

          -  Appropriate motivation and expectation levels

          -  Stated willingness to comply with all study procedures for the duration of the study

        Exclusion Criteria:

          -  Evidence that hearing loss is retrocochlear in origin

          -  Active middle ear infection

          -  Skin or scalp condition precluding use of external audio processor- Suspected
             cognitive impairment or organic brain dysfunction

          -  History of prior use of a hearing implant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew Fitzgerald, PhD</last_name>
      <phone>650-724-6015</phone>
      <email>fitzmb@stanford.edu</email>
    </contact>
    <contact_backup>
      <last_name>Janine Larky, MA</last_name>
      <phone>650-736-0294</phone>
      <email>jlarky@stanford.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Matthew Fitzgerald, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Janine Larky, MA</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandy Prentiss, AuD</last_name>
      <phone>305-243-1667</phone>
      <email>s.prentiss@med.miami.edu</email>
    </contact>
    <contact_backup>
      <last_name>Constanza Pelluso</last_name>
      <phone>305-243-7102</phone>
      <email>cpelusso@med.miami.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Fred Telischi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sandy Prentiss, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of North Carolina</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margaret Dillon, AuD</last_name>
      <phone>919-966-5251</phone>
      <email>mdillon@med.unc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Meredith Rooth, AuD</last_name>
      <phone>919-966-5251</phone>
      <email>meredith_rooth@med.unc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Margaret Dillon, AuD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Meredith Rooth, AuD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sara Unrein, AuD</last_name>
      <phone>615-322-0333</phone>
      <email>sara.c.unrein@vumc.org</email>
    </contact>
    <contact_backup>
      <last_name>Ashudee M Kirk, MS</last_name>
      <phone>615-322-0333</phone>
      <email>ashudee.kirk@vumc.org</email>
    </contact_backup>
    <investigator>
      <last_name>David Haynes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sara Unrein, AuD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christina Runge, PhD</last_name>
      <phone>414-955-0822</phone>
      <email>crunge@mcw.edu</email>
    </contact>
    <contact_backup>
      <last_name>Sarah Mleziva</last_name>
      <phone>414-955-0822</phone>
      <email>smleziva@mcw.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Christina Runge</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kari Smilsky, M.CI.Sc</last_name>
      <phone>416-480-6100</phone>
      <email>Kari.smilsky@sunnybrook.ca</email>
    </contact>
    <contact_backup>
      <last_name>Varia Sajeniouk, CRC</last_name>
      <phone>416-480-6100</phone>
      <email>varia.sajeniouk@sunnybrook.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Kari Smilsky, M.Cl.Sc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Amoodi HA, Mick PT, Shipp DB, Friesen LM, Nedzelski JM, Chen JM, Lin VY. Results with cochlear implantation in adults with speech recognition scores exceeding current criteria. Otol Neurotol. 2012 Jan;33(1):6-12. doi: 10.1097/MAO.0b013e318239e5a1.</citation>
    <PMID>22090001</PMID>
  </reference>
  <reference>
    <citation>Bassim MK, Buss E, Clark MS, Kolln KA, Pillsbury CH, Pillsbury HC 3rd, Buchman CA. MED-EL Combi40+ cochlear implantation in adults. Laryngoscope. 2005 Sep;115(9):1568-73.</citation>
    <PMID>16148696</PMID>
  </reference>
  <reference>
    <citation>Cox RM, Alexander GC. The abbreviated profile of hearing aid benefit. Ear Hear. 1995 Apr;16(2):176-86.</citation>
    <PMID>7789669</PMID>
  </reference>
  <reference>
    <citation>Cullen RD, Higgins C, Buss E, Clark M, Pillsbury HC 3rd, Buchman CA. Cochlear implantation in patients with substantial residual hearing. Laryngoscope. 2004 Dec;114(12):2218-23.</citation>
    <PMID>15564849</PMID>
  </reference>
  <reference>
    <citation>Dorman MF, Gifford RH, Spahr AJ, McKarns SA. The benefits of combining acoustic and electric stimulation for the recognition of speech, voice and melodies. Audiol Neurootol. 2008;13(2):105-12. Epub 2007 Nov 29.</citation>
    <PMID>18057874</PMID>
  </reference>
  <reference>
    <citation>Gantz BJ, Turner C, Gfeller KE. Acoustic plus electric speech processing: preliminary results of a multicenter clinical trial of the Iowa/Nucleus Hybrid implant. Audiol Neurootol. 2006;11 Suppl 1:63-8. Epub 2006 Oct 6.</citation>
    <PMID>17063013</PMID>
  </reference>
  <reference>
    <citation>Gatehouse S, Noble W. The Speech, Spatial and Qualities of Hearing Scale (SSQ). Int J Audiol. 2004 Feb;43(2):85-99.</citation>
    <PMID>15035561</PMID>
  </reference>
  <reference>
    <citation>Gifford RH, Dorman MF, McKarns SA, Spahr AJ. Combined electric and contralateral acoustic hearing: word and sentence recognition with bimodal hearing. J Speech Lang Hear Res. 2007 Aug;50(4):835-43.</citation>
    <PMID>17675589</PMID>
  </reference>
  <reference>
    <citation>Gifford RH, Dorman MF, Shallop JK, Sydlowski SA. Evidence for the expansion of adult cochlear implant candidacy. Ear Hear. 2010 Apr;31(2):186-94. doi: 10.1097/AUD.0b013e3181c6b831.</citation>
    <PMID>20071994</PMID>
  </reference>
  <reference>
    <citation>Gifford RH, Dorman MF, Skarzynski H, Lorens A, Polak M, Driscoll CL, Roland P, Buchman CA. Cochlear implantation with hearing preservation yields significant benefit for speech recognition in complex listening environments. Ear Hear. 2013 Jul-Aug;34(4):413-25. doi: 10.1097/AUD.0b013e31827e8163.</citation>
    <PMID>23446225</PMID>
  </reference>
  <reference>
    <citation>Gifford RH, Shallop JK, Peterson AM. Speech recognition materials and ceiling effects: considerations for cochlear implant programs. Audiol Neurootol. 2008;13(3):193-205. doi: 10.1159/000113510. Epub 2008 Jan 22.</citation>
    <PMID>18212519</PMID>
  </reference>
  <reference>
    <citation>Nilsson M, Soli SD, Sullivan JA. Development of the Hearing in Noise Test for the measurement of speech reception thresholds in quiet and in noise. J Acoust Soc Am. 1994 Feb;95(2):1085-99.</citation>
    <PMID>8132902</PMID>
  </reference>
  <reference>
    <citation>PETERSON GE, LEHISTE I. Revised CNC lists for auditory tests. J Speech Hear Disord. 1962 Feb;27:62-70.</citation>
    <PMID>14485785</PMID>
  </reference>
  <reference>
    <citation>Skarzynski H, van de Heyning P, Agrawal S, Arauz SL, Atlas M, Baumgartner W, Caversaccio M, de Bodt M, Gavilan J, Godey B, Green K, Gstoettner W, Hagen R, Han DM, Kameswaran M, Karltorp E, Kompis M, Kuzovkov V, Lassaletta L, Levevre F, Li Y, Manikoth M, Martin J, Mlynski R, Mueller J, O'Driscoll M, Parnes L, Prentiss S, Pulibalathingal S, Raine CH, Rajan G, Rajeswaran R, Rivas JA, Rivas A, Skarzynski PH, Sprinzl G, Staecker H, Stephan K, Usami S, Yanov Y, Zernotti ME, Zimmermann K, Lorens A, Mertens G. Towards a consensus on a hearing preservation classification system. Acta Otolaryngol Suppl. 2013;(564):3-13. doi: 10.3109/00016489.2013.869059.</citation>
    <PMID>24328756</PMID>
  </reference>
  <reference>
    <citation>Spahr AJ, Dorman MF, Litvak LM, Van Wie S, Gifford RH, Loizou PC, Loiselle LM, Oakes T, Cook S. Development and validation of the AzBio sentence lists. Ear Hear. 2012 Jan-Feb;33(1):112-7. doi: 10.1097/AUD.0b013e31822c2549.</citation>
    <PMID>21829134</PMID>
  </reference>
  <reference>
    <citation>Verschuur C, Hellier W, Teo C. An evaluation of hearing preservation outcomes in routine cochlear implant care: Implications for candidacy. Cochlear Implants Int. 2016 Apr;17 Suppl 1:62-5. doi: 10.1080/14670100.2016.1152007.</citation>
    <PMID>27099115</PMID>
  </reference>
  <reference>
    <citation>Vickers D, De Raeve L, Graham J. International survey of cochlear implant candidacy. Cochlear Implants Int. 2016 Apr;17 Suppl 1:36-41. doi: 10.1080/14670100.2016.1155809.</citation>
    <PMID>27099109</PMID>
  </reference>
  <reference>
    <citation>von Ilberg CA, Baumann U, Kiefer J, Tillein J, Adunka OF. Electric-acoustic stimulation of the auditory system: a review of the first decade. Audiol Neurootol. 2011;16 Suppl 2:1-30. doi: 10.1159/000327765. Epub 2011 May 24. Review.</citation>
    <PMID>21606646</PMID>
  </reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>July 28, 2017</study_first_submitted>
  <study_first_submitted_qc>July 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 2, 2017</study_first_posted>
  <last_update_submitted>February 25, 2020</last_update_submitted>
  <last_update_submitted_qc>February 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hearing Loss</mesh_term>
    <mesh_term>Hearing Loss, Sensorineural</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

